Key result
Edoxaban reduces thrombus volume by ~27% vs placebo by enhancing spontaneous thrombolysis, without altering atherosclerosis.
Why the study?
The details of thrombolytic activity in occlusive disease associated with atherosclerotic lesions are not clear.
Answers are grounded in this paper and cite their sources.
May enhance spontaneous thrombolysis in animal models without affecting atherosclerosis; hypothesis-generating and should not change practice.
The details of thrombolytic activity in occlusive disease associated with atherosclerotic lesions are not clear. This study investigated the novel effects of activated coagulation factor X (F-Xa)-directed oral anticoagulant (DOAC) edoxaban on in vivo thrombolytic activity and atherosclerosis progression.
No takes yet. Share an insight, caveat, or question.
Kanae et al. (2022) studied Atherosclerosis and thrombosis (Apoe-/- and Ldlr-/- double knockout mice) (n=65). Edoxaban vs. Placebo was evaluated on Thrombus volume at 60 minutes as a percentage of initial volume (p=<0.01). Edoxaban at /kg enhanced spontaneous thrombolytic activity, reducing thrombus volume to 47.4% of initial volume compared to 65.3% with placebo, without affecting atherosclerosis.
Synapse has enriched 10 related papers. Consider them for comparative context: